You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

CLINICAL TRIALS PROFILE FOR INTRALIPID 20%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Intralipid 20%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005889 ↗ Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status Baylor College of Medicine N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 ↗ Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status National Center for Research Resources (NCRR) N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00048646 ↗ Progesterone Treatment of Blunt Traumatic Brain Injury Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1/Phase 2 2002-05-01 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00048646 ↗ Progesterone Treatment of Blunt Traumatic Brain Injury Completed David Wright Phase 1/Phase 2 2002-05-01 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Intralipid 20%

Condition Name

Condition Name for Intralipid 20%
Intervention Trials
Parenteral Nutrition 6
Obesity 6
Cholestasis 5
Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Intralipid 20%
Intervention Trials
Insulin Resistance 10
Cholestasis 8
Liver Diseases 5
Infertility 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Intralipid 20%

Trials by Country

Trials by Country for Intralipid 20%
Location Trials
United States 76
Canada 14
Egypt 9
France 4
Netherlands 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Intralipid 20%
Location Trials
New York 7
Texas 6
Massachusetts 5
Tennessee 5
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Intralipid 20%

Clinical Trial Phase

Clinical Trial Phase for Intralipid 20%
Clinical Trial Phase Trials
Phase 4 27
Phase 3 11
Phase 2/Phase 3 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Intralipid 20%
Clinical Trial Phase Trials
Completed 45
Terminated 9
Recruiting 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Intralipid 20%

Sponsor Name

Sponsor Name for Intralipid 20%
Sponsor Trials
Fresenius Kabi 5
Emory University 5
Baxter Healthcare Corporation 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Intralipid 20%
Sponsor Trials
Other 94
Industry 21
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Intralipid 20%: Clinical Trials, Market Analysis, and Projections

Introduction

Intralipid 20%, a 20% intravenous fat emulsion, is a critical component in parenteral nutrition, providing essential calories and fatty acids to patients who cannot receive nutrition through oral or enteral means. This article delves into the current clinical trials, market analysis, and future projections for Intralipid 20%.

Clinical Trials Overview

Ongoing and Completed Trials

Several clinical trials have been conducted or are ongoing to evaluate the safety and efficacy of Intralipid 20% compared to other lipid emulsions.

  • Comparison with Smoflipid: A Phase 3 study (NCT02579265) aimed to compare the safety and efficacy of Smoflipid 20% to Intralipid 20% in hospitalized neonates and infants requiring 28 days of parenteral nutrition. The primary outcome was to show the superiority of Smoflipid in safety by measuring the number of patients with conjugated bilirubin exceeding 2 mg/dL during the first 28 days of treatment[1].

  • Evaluation in Pediatric Patients: A Phase 4 study (NCT04555044) evaluated the risk of developing essential fatty acid deficiency (EFAD) in pediatric patients, including preterm and term neonates, receiving Intralipid 20% versus lipid injectable emulsion. The study found no participants in either group developed EFAD defined by the Holman Index > 0.4[4].

Market Analysis

Market Segmentation

The lipid injectable drugs market, which includes Intralipid 20%, is segmented by type, application, and region.

  • Type: The market includes Intralipid, Liposyn III, Smoflipid, and Clinolipid. Intralipid 20% is a prominent player in this segment due to its widespread use in parenteral nutrition[2].

  • Application: The primary applications include pain reduction, toxicity reduction, and targeted drug delivery. Intralipid 20% is primarily used for providing calories and essential fatty acids in parenteral nutrition[2].

Market Growth Drivers

Several factors are driving the growth of the lipid injectable drugs market, including:

  • Technological Advancements: Innovations in lipid-based drug delivery systems enhance drug solubility, bioavailability, and targeted delivery, making them effective for chronic conditions[2].

  • Nanotechnology and Personalized Treatment: Advances in nanotechnology and personalized medicine are leading to novel lipid-based formulations with improved therapeutic efficacy and fewer side effects[2].

  • Emerging Opportunities in Biosimilars and Generic Drugs: The increasing adoption of biosimilars and generic lipid injectable drugs is making treatments more affordable and accessible[2].

Market Size and Projections

The lipid injectable drugs market is expected to register a Compound Annual Growth Rate (CAGR) of 8.8% from 2023 to 2031. The market size is projected to expand from US$ XX million in 2023 to US$ XX Million by 2031[2].

Regional Insights

The lipid injectable drugs market is analyzed at the regional level, including North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Each region has its unique trends and factors influencing the market growth.

  • North America: This region is expected to be a significant market due to advanced healthcare infrastructure and high adoption rates of innovative medical technologies[2].

Product Description and Usage

Composition

Intralipid 20% is a sterile, non-pyrogenic fat emulsion made of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. The pH is adjusted with sodium hydroxide to a range of 6 to 8.9[5].

Administration

It is administered intravenously as a source of calories and essential fatty acids. The flow rate is typically prescribed to provide the daily dosage over 20 to 24 hours, ensuring the maximum lipid infusion rate does not exceed 0.15 g/kg/hour[4].

Side Effects and Safety Profile

Intralipid 20% is generally well-tolerated, but like any medical product, it can have side effects. Common side effects include hyperlipidemia, hypertriglyceridemia, and allergic reactions. Serious side effects can include fat overload syndrome and severe hypersensitivity reactions[5].

Regulatory Updates

FDA Approvals

The FDA has been involved in various regulatory updates related to lipid injectable emulsions. For instance, the FDA expanded the label for lipid injectable emulsion (Clinolipid) to include use in pediatric patients, including preterm and term neonates, based on clinical trial data[4].

Future Projections

Market Expansion

The growing demand for effective and safe parenteral nutrition solutions, coupled with advancements in lipid-based drug delivery systems, is expected to drive the market for Intralipid 20% and similar products. The increasing prevalence of chronic diseases and the need for targeted drug delivery will continue to fuel market growth[2].

Technological Innovations

Future innovations in nanotechnology and personalized medicine are likely to enhance the therapeutic efficacy and safety profile of Intralipid 20% and other lipid injectable drugs. This could lead to new applications and expanded use in various clinical settings[2].

Key Takeaways

  • Clinical Trials: Ongoing and completed trials compare Intralipid 20% with other lipid emulsions, focusing on safety and efficacy in various patient populations.
  • Market Growth: The lipid injectable drugs market is expected to grow at a CAGR of 8.8% from 2023 to 2031, driven by technological advancements and increasing demand for parenteral nutrition.
  • Regional Insights: North America and other regions are expected to contribute significantly to the market growth due to advanced healthcare infrastructure and high adoption rates of innovative technologies.
  • Product Usage: Intralipid 20% is administered intravenously to provide essential calories and fatty acids, with a focus on maintaining safe infusion rates.
  • Regulatory Updates: FDA approvals and label expansions are crucial for the broader use of lipid injectable emulsions in pediatric and adult populations.

FAQs

Q: What is Intralipid 20% used for?

Intralipid 20% is used as a source of calories and essential fatty acids in parenteral nutrition for patients who cannot receive nutrition through oral or enteral means.

Q: What are the main components of Intralipid 20%?

Intralipid 20% is composed of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection, with the pH adjusted by sodium hydroxide.

Q: What are the potential side effects of Intralipid 20%?

Common side effects include hyperlipidemia, hypertriglyceridemia, and allergic reactions. Serious side effects can include fat overload syndrome and severe hypersensitivity reactions.

Q: How is Intralipid 20% administered?

It is administered intravenously, with the flow rate prescribed to provide the daily dosage over 20 to 24 hours, ensuring the maximum lipid infusion rate does not exceed 0.15 g/kg/hour.

Q: What is the expected market growth for Intralipid 20% and similar products?

The lipid injectable drugs market, which includes Intralipid 20%, is expected to register a CAGR of 8.8% from 2023 to 2031.

References

  1. Stanford University Clinical Trials: Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants.
  2. The Insight Partners: Lipid Injectable Drugs Market Insights and Growth by 2031.
  3. Straits Research: Global Clinical Trials Market Size, Top Share, Trends, Forecast by 2024-2031.
  4. Contemporary Pediatrics: FDA expands label for lipid injectable emulsion to preterm and term neonates.
  5. RxList: Intralipid 20% (20% I.V. Fat Emulsion): Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.